Upadacitinib for the treatment of rheumatoid arthritis following previous therapy with biologics or JAK inhibitors
In 2020, the Institute for Quality and Efficiency in Health Care (IQWiG, Germany) looked into whether upadacitinib has any advantages or disadvantages compared with the standard treatment in adults who did not benefit enough from – or who cannot tolerate – treatment with one or more biologics or JAK inhibitors.
The manufacturer provided one relevant study. The IQWiG researchers used the data on about 450 patients in their analysis. One half of these patients were given upadacitinib, and the other half received abatacept. Both groups received methotrexate (MTX) too.
The following results were found after half a year: